HER2-PET Imaging for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug 89Zr-trastuzumab for HER2-PET imaging in breast cancer?
Research shows that 89Zr-trastuzumab PET imaging can help identify HER2-positive breast cancer lesions, even in cases where standard methods struggle to determine HER2 status. This imaging technique can also predict how well patients respond to pre-surgery treatments, potentially reducing the need for surgery.12345
Is 89Zr-trastuzumab safe for use in humans?
How is HER2-PET Imaging for Breast Cancer different from other treatments?
HER2-PET Imaging for Breast Cancer is unique because it uses a special imaging technique with a tracer called 89Zr-trastuzumab to detect HER2-positive cancer cells, even when standard tests can't determine HER2 status. This approach helps in making more informed treatment decisions and can identify HER2-positive metastases in patients who initially had HER2-negative breast cancer.23459
What is the purpose of this trial?
A strategy to target the oncogenic receptor HER2 using a version of the anti-HER2 therapeutic antibody trastuzumab coupled to desferrioxamine (DFO) and radiolabeled with zirconium-89 (\[89Zr\]-DFO-trastuzumab) has been successfully evaluated in our group in preclinical settings. Clinical studies by other groups in recent years have shown the potential of targeting HER2+ lesions with \[89Zr\]-DFO-trastuzumab in patients with HER2+ cancers. We now want to establish the diagnostic potential of a protocol adding \[89Zr\]-DFO-trastuzumab PET imaging to FDG PET already used in the clinic for the detection of HER2-expressing cancers, including low expression levels considered until now as HER2-negative (HER2-low, IHC score 1+ and 2+ without FISH amplification of the HER2 locus). The HER2-low status has recently gained relevance thanks to large studies showing the efficacy of immunotherapy combined with drugs such as Enhertu (trastuzumab-deruxtecan), while trastuzumab alone was traditionally only effective for HER2+ cancers (IHC score 2+/FISH+, or 3+). In particular, we aim to develop a method to assess whole-body intertumoral heterogeneity in HER2 expression in order to detect cases with heterogeneous diseases and thus better stage patients and guide the optimal choice of personalized and targeted treatment to use. More specifically, the project aims to image with \[89Zr\]-DFO-trastuzumab PET patients with cancer, particularly breast cancer, but also esophageal, gastric, ovarian, endometrial and lung cancer, and whose primary tumor status is HER2-low.
Research Team
Éric E Turcotte, MD, FRCPC
Principal Investigator
Université de Sherbrooke
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an intravenous dose of trastuzumab followed by 89Zr-trastuzumab, with PET/CT imaging conducted 3-6 days later
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- 89Zr-trastuzumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Lead Sponsor
Université de Sherbrooke
Collaborator